Management of patients with familial hypercholesterolaemia

Nature Reviews Cardiology

Volumn 12, Issue 10, 2015, Pages 565-575

  Reiner, Zeljko ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; BILE ACID SEQUESTRANT; BOCOCIZUMAB; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; HYPOCHOLESTEROLEMIC AGENT;

APHERESIS; CHILDHOOD; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE THERAPY; HUMAN; LIVER TRANSPLANTATION; MONOTHERAPY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; DISEASE MANAGEMENT; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; PRACTICE GUIDELINE; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; DISEASE MANAGEMENT; GENETIC THERAPY; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIVER TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RISK FACTORS;

EID: 84941877077     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2015.92     Document Type: Review

References (111)

1. Nordestgaard B. G., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34, 3478-3490 (2013
2. WHO. International Classification of Diseases (ICD) [online], http://www.who.int/classifications/icd/en/(2015
3. Brown M. S., & Goldstein J. L. A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34-47 (1986
4. Goldstein J. L., & Brown M. S. Familial hypercholesterolemia: identification of a defect in the regulation of 3 hydroxy 3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc. Natl Acad. Sci. USA 70, 2804-2808 (1973
5. Brown M. S., & Goldstein J. L. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3 hydroxy 3-methylglutaryl coenzyme A reductase activity. Proc. Natl Acad. Sci. USA 71, 788-792 (1974
6. Leiden Open (source) Variation Database (LOVD). Low-density lipoprotein receptor [online], http://www.ucl.ac.uk/ldlr/LOVDv.1.1.0/(2011
7. Abifadel M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156 (2003
8. Soutar A. K., Naoumova R. P., & Traub L. M. Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 23, 1963-1970 (2003
9. Tada H., et al. Autosomal recessive hypercholesterolemia: a mild phenotype of familial hypercholesterolemia: insight from the kinetic study using stable isotope and animal studies. J. Atheroscler. Thromb. 22, 1-9 (2015
10. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 303, 893-896 (1991
11. Williams R. R., et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 72, 171-176 (1993
12. WHO Familial Hypercholesterolemia Consultation Group. Familial Hypercholesterolemia. Report of a WHO Consultation [online], http://whqlibdoc.who.int/hq/1999/WHO-HGN-FH-CONS-99.2.pdf (1998
13. Defesche J. C., et al. Advanced method for the identification of patients with inherited hypercholesterolemia. Semin. Vasc. Med. 4, 59-65 (2004
14. Weng S. F., et al. Improving identification of familial hypercholesterolaemia in primary care: derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT). Atherosclerosis 238, 336-343 (2015
15. Ademi Z., et al. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. Clin. Lipidol. 8, 390-400 (2014
16. Bell D. A., et al. Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience. Atherosclerosis 239, 93-100 (2015
17. Jannes C. E., et al. Familial hypercholesterolemia in Brazil: cascade screening program, clinical and genetic aspects. Atherosclerosis 238, 101-107 (2015
18. George R., Kovak K., & Cox S. L. Aligning policy to promote cascade genetic screening for prevention and early diagnosis of heritable diseases. J. Genet. Couns. 24, 388-399 (2015
19. Taylor A., et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin. Genet. 77, 572-580 (2010
20. Whittall R. A., et al. Development of a high-resolution melting method for mutation detection in familial hypercholesterolaemia patients. Ann. Clin. Biochem. 47, 44-55 (2010
21. Pećin I., et al. Mutation detection in Croatian patients with familial hypercholesterolemia. Ann. Hum. Genet. 77, 22-30 (2013
22. Benn M., et al. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J. Clin. Endocrinol. Metab. 97, 3956-3964 (2012
23. Cuchel M., et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur. Heart J. 35, 2146-2157 (2014
24. Widhalm K., et al. Sudden death in a 4 year old boy: a near-complete occlusion of the coronary artery caused by an aggressive lipoprotein receptor mutation (W556R) in homozygous familial hypercholesterolemia. J. Pediatr. 158, 167 (2011
25. De Backer G., et al. Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV. Atherosclerosis 241, 169-175 (2015
26. Mundal L., et al. Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010. J. Am. Heart Assoc. 3, e001236 (2014
27. Reiner Ž., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32, 1769-1818 (2011
28. Reiner Ž. New ESC/EAS Guidelines for the management of dyslipidaemias-any controversies behind the consensus?. Eur. J. Cardiovasc. Prev. Rehabil. 18, 724-727 (2011
29. Perk J., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur. Heart J. 33, 1635-1701 (2012
30. Stone N. J., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, S1-S45 (2014
31. Reiner Ž. A comparison of European and US guidelines for familial hypercholesterolemia. Curr. Opin. Lipidol. 26, 215-220 (2015
32. Jansen A. C., et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J. Intern. Med. 256, 482-490 (2004
33. Reiner Ž. Statins in the primary prevention of cardiovascular disease. Nat. Rev. Cardiol. 10, 453-464 (2013
34. Versmissen J., et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 337, a2423 (2008
35. Neil A., et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur. Heart J. 29, 2625-2633 (2008
36. Elis A., Zhou R., & Stein E. A. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. Am. J. Cardiol. 108, 223-226 (2011
37. Smilde T. J., et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357, 577-581 (2001
38. Raal F. J., et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 124, 2202-2207 (2011
39. Marais A. D., Firth J. C., & Blom D. J. Homozygous familial hypercholesterolemia and its management. Semin. Vasc. Med. 4, 43-50 (2004
40. Reiner Ž. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr. Metab. Cardiovasc. Dis. 23, 799-807 (2013
41. Šimić, I., & Reiner Ž. Adverse effects of statins-myths and reality. Curr. Pharm. Des. 21, 218-225 (2015
42. Preiss D., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305, 2556-2564 (2011
43. Skoumas J., et al. Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia. Atherosclerosis 237, 140-145 (2014
44. Pijlman A. H., et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 209, 189-194 (2010
45. Galema-Boers J. M., et al. Predicting non-adherence in patients with familial hypercholesterolemia. Eur. J. Clin. Pharmacol. 70, 391-397 (2014
46. Reiner Ž., Sonicki Z., & Tedeschi-Reiner E. Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey. Prev. Med. 51, 494-496 (2010
47. Reiner Ž., Sonicki Z., & Tedeschi-Reiner E. Physicians perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis 213, 598-603 (2010
48. Reiner Ž., & Tedeschi-Reiner E. Prevalence and types of persistent dyslipidemia in patients treated with statins. Croat. Med. J. 54, 339-345 (2013
49. Reiner Ž. Resistance and intolerance to statins. Nutr. Metab. Cardiovasc. Dis. 24, 1057-1066 (2014
50. Reiner Ž. Combined therapy in the treatment of dyslipidemia. Fundam. Clin. Pharmacol. 24, 19-28 (2010
51. Blazing M. A., et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am. Heart J. 168, 205-212 (2014
52. Cannon C. P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1410489
53. Kastelein J. J., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431-1443 (2008
54. Gagne C., Gaudet D., & Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105, 2469-2475 (2002
55. Tuteja S., et al. Simvastatin ezetimibe-induced hepatic failure necessitating liver transplantation. Pharmacotherapy 28, 1188-1193 (2008
56. Castellote J., et al. Serious drug-induced liver disease secondary to ezetimibe. World J. Gastroenterol. 14, 5098-5099 (2008
57. Witztum J. L., et al. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride. Circulation 79, 16-28 (1989
58. Wendelhag I., Wiklund O., & Wikstrand J. Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. A three-year ultrasound study of common carotid and femoral arteries. Atherosclerosis 117, 225-236 (1995
59. Kajinami K., et al. Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia. Am. J. Cardiol. 82, 113-117 (1998
60. Kawashiri M. A., et al. Efficacy of colestimide coadministered with atorvastatin in japanese patients with heterozygous familial hypercholesterolemia (FH). Circ. J. 69, 515-520 (2005
61. Davidson M. The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients. Clin. Ther. 35, 1247-1252 (2013
62. Huijgen R., et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther. 32, 615-625 (2010
63. Stein E. A., et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J. Pediatr. 156, 231-236 (2010
64. Thompson G. R., et al. Recommendations for the use of LDL apheresis. Atherosclerosis 98, 247-255 (2008
65. Koga N. The retardation of progression, stabilization, and regression of coronary and carotid atherosclerosis by low-density lipoprotein apheresis in patients with familial hypercholesterolemia. J. Intern. Med. 246, 35-43 (1999
66. van Buuren F., et al. HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures. Clin. Res. Cardiol. 7, 24-30 (2012
67. Thompson G. R. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler. Suppl. 14, 67-70 (2013
68. Schuff-Werner P., Fenger S., & Kohlschein P. Role of lipid apheresis in changing times. Clin. Res. Cardiol. Suppl. 7, 7-14 (2012
69. Dumić, M., et al. Three year old boy-a homozygote for familiar hypercholesterolemia [Croatian]. Lijec. Vjesn. 129, 130-133 (2007
70. Hudgins L. C., et al. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am. J. Cardiol. 102, 1199-1204 (2008
71. Stefanutti C., & Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler. Suppl. 14, 19-27 (2013
72. Raal F. J., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375, 998-1006 (2010
73. McGowan M. P., et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE 7, e49006 (2012
74. Thomas G. S., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 62, 2178-2184 (2013
75. Stein E. A., et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126, 2283-2292 (2012
76. Cuchel M., et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356, 148-156 (2007
77. Cuchel M., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381, 40-46 (2013
78. Raal F. J. Lomitapide for homozygous familial hypercholesterolaemia. Lancet 381, 7-8 (2013
79. Tuteja S., et al. Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia. Pharmacotherapy 34, 227-239 (2014
80. Cohen J. C., Boerwinkle E., Mosley T. H. Jr., & Hobbs H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272 (2006
81. McKenney J. M., et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59, 2344-2353 (2012
82. Stein E. A., et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 380, 29-36 (2012
83. Gaudet D., et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am. J. Cardiol. 114, 711-715 (2014
84. Koren M. J., et al. Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: a phase II pooled analysis. Postgrad. Med. 22, 1-8 (2015
85. Kastelein J. J., et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc. Drugs Ther. 28, 281-289 (2014
86. Robinson J. G., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1489-1499 (2015
87. Dias C. S., et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J. Am. Coll. Cardiol. 60, 1888-1898 (2012
88. Raal F., et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (rutherford) randomized trial. Circulation 126, 2408-2417 (2012
89. Stein E. A., et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128, 2113-2120 (2013
90. Raal F. J., et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD 2): a randomised, double-blind, placebo-controlled trial. Lancet 385, 331-340 (2014
91. Raal F. J., et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385, 341-350 (2015
92. Sabatine M. S., et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1500-1509 (2015
93. US National Institutes of Health. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01968980 (2015
94. Ballantyne C. M., et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am. J. Cardiol. 115, 1212-1221 (2015
95. Schwartz G. G., et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am. Heart J. 168, 682-689 (2014
96. US National Institutes of Health. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01764633 (2015
97. Bilheimer D. W., et al. Liver transplantation to provide low density lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N. Engl. J. Med. 311, 1658-1664 (1984
98. Starzl T. E., et al. Heart-liver transplantation in a patient with familial hypercholesterolaemia. Lancet 1, 1382-1383 (1984
99. Hoeg J. M., Starzl T. E., & Brewer H. B. Jr. Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia. Am. J. Cardiol. 59, 705-707 (1987
100. Maiorana A., et al. Preemptive liver transplantation in a child with familial hypercholesterolemia. Pediatr. Transplant. 15, E25-E29 (2011
101. Al-Allaf F. A., et al. LDLR-gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives. Int. Arch. Med. 3, 36 (2010
102. Grossman M., et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat. Genet. 6, 335-341 (1994
103. Grossman M., et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat. Med. 1, 1148-1154 (1995
104. Nomura S., et al. Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia. Gene Ther. 11, 1540-1548 (2004
105. Oka K., et al. Gene therapy for rhesus monkeys heterozygous for LDL receptor deficiency by balloon catheter hepatic delivery of helper-dependent adenoviral vector. Gene Ther. 22, 87-95 (2015
106. Berenson G. S., et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N. Engl. J. Med. 338, 1650-1656 (1998
107. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 128, S213-S256 (2011
108. Reiner Ž. The impact of early evidence of atherosclerotic changes on early treatment in children with familial hypercholesterolemia. Circ. Res. 114, 233-235 (2014
109. Kusters D. M., et al. Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemia. J. Clin. Lipidol. 7, 408-413 (2013
110. Pang J., et al. Significant gaps in awareness of familial hypercholesterolemia among physicians in selected Asia-Pacific countries: a pilot study. J. Clin. Lipidol. 9, 42-48 (2015
111. WHO Human Genetics Programme. Familial hypercholesterolaemia (FH): report of a second WHO consultation [online], http://apps.who.int/iris/handle/10665/66346 (1999